Reduction of New Heterotopic Ossification ( <scp>HO</scp> ) in the <scp>Open‐Label</scp> , Phase 3 <scp>MOVE</scp> Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva ( <scp>FOP</scp> )-Reference-Cited by-同舟云学术

Reduction of New Heterotopic Ossification ( HO ) in the Open‐Label , Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva ( FOP )

Published:2023-01-25 Issue:3 Volume:38 Page:381-394
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J of Bone & Mineral Res

Author:

Pignolo Robert J.¹^ORCID,Hsiao Edward C.²,Al Mukaddam Mona³,Baujat Geneviève⁴,Berglund Staffan K.⁵,Brown Matthew A.⁶⁷,Cheung Angela M.⁸^ORCID,De Cunto Carmen⁹,Delai Patricia¹⁰,Haga Nobuhiko¹¹,Kannu Peter¹²,Keen Richard¹³,Le Quan Sang Kim‐Hanh⁴,Mancilla Edna E.¹⁴,Marino Rose¹⁵,Strahs Andrew¹⁵,Kaplan Frederick S.³

Affiliation:

1. Department of Medicine Mayo Clinic Rochester MN USA

2. Division of Endocrinology and Metabolism, the UCSF Metabolic Bone Clinic, the Eli and Edythe Broad Institute for Regeneration Medicine, and the Institute of Human Genetics, Department of Medicine, and the UCSF Program in Craniofacial Biology University of California‐San Francisco San Francisco CA USA

3. Departments of Orthopaedic Surgery & Medicine, The Center for Research in FOP and Related Disorders, Perelman School of Medicine University of Pennsylvania Philadelphia PA USA

4. Département de Génétique Institut IMAGINE and Hôpital Universitaire Necker‐Enfants Malades Paris France

5. Department of Clinical Sciences, Pediatrics Umeå University Umeå Sweden

6. Faculty of Life Sciences and Medicine King's College London London UK

7. Genomics England Ltd London UK

8. Department of Medicine and Joint Department of Medical Imaging, University Health Network University of Toronto Toronto ON Canada

9. Pediatric Rheumatology Section, Department of Pediatrics Hospital Italiano de Buenos Aires Buenos Aires Argentina

10. Centro de Pesquisa Clinica Hospital Israelita Albert Einstein São Paulo Brazil

11. Department of Rehabilitation Medicine The University of Tokyo Hospital Tokyo Japan

12. Hospital for Sick Children Toronto ON Canada

13. Centre for Metabolic Bone Disease Royal National Orthopaedic Hospital Stanmore UK

14. Children's Hospital of Philadelphia, Perelman School of Medicine University of Pennsylvania Philadelphia PA USA

15. Ipsen Cambridge MA USA

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jbmr.4762

Reference64 articles.

1. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva

2. Epidemiology of the Global Fibrodysplasia Ossificans Progressiva (FOP) Community

3. Inherited human diseases of heterotopic bone formation

4. The phenotype and genotype of fibrodysplasia ossificans progressiva in China: A report of 72 cases

5. The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP‐independent chondrogenesis and zebrafish embryo ventralization;Shen Q;J Clin Invest.,2009

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A fibrodysplasia ossificans progressiva patient with a rare missense mutation in ACVR1 detected on 18F-FDG PET/CT;Joint Bone Spine;2024-03

2. The roles and regulatory mechanisms of TGF-β and BMP signaling in bone and cartilage development, homeostasis and disease;Cell Research;2024-01-24

3. The HIF-1α and mTOR Pathways Amplify Heterotopic Ossification;Biomolecules;2024-01-24

4. Navigating the Complex Landscape of Fibrodysplasia Ossificans Progressiva: From Current Paradigms to Therapeutic Frontiers;Genes;2023-11-30

5. TO MARKET, TO MARKET–2022: SMALL MOLECULES;Medicinal Chemistry Reviews;2023-11-16